Sanofi: publication about Dupixent in a scientific review

(CercleFinance.com) - The pharmaceutical group Sanofi announced that the New England Journal of Medicine has published positive results of the two phase III clinical trials - QUEST and VENTURE - showing that Dupixent (dupilumab) improves moderate-to-severe asthma.


These results indicate that Dupixent significantly reduced the risk of severe asthma attacks (exacerbations), improved patients' breathing function and decreased their dependence on orally administered corticosteroids.

The experimental use of Dupixent in the complementary maintenance of moderate-to-severe asthma in adults and teenagers is currently being evaluated by regulatory agencies in several countries, including the US, Japan and the EU.


Copyright (c) 2018 CercleFinance.com. All rights reserved.